Global Biosimilars & Follow-on-biologics Market Growth (Status and Outlook) 2023-2029

Global Biosimilars & Follow-on-biologics Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Biosimilars & Follow-on-biologics Industry Forecast” looks at past sales and reviews total world Biosimilars & Follow-on-biologics sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilars & Follow-on-biologics sales for 2023 through 2029. With Biosimilars & Follow-on-biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilars & Follow-on-biologics industry.

This Insight Report provides a comprehensive analysis of the global Biosimilars & Follow-on-biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilars & Follow-on-biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilars & Follow-on-biologics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilars & Follow-on-biologics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilars & Follow-on-biologics.

The global Biosimilars & Follow-on-biologics market size is projected to grow from US$ 9089.2 million in 2022 to US$ 11310 million in 2029; it is expected to grow at a CAGR of 3.2% from 2023 to 2029.

Biosimilars or follow-on-biologics are the “copied” and licensed versions of those reference biologics that have undergone patent expiration. Biosimilars development and validation with reference biologics is a crucial aspect of the overall development process. 

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilars & Follow-on-biologics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Human growth hormone
Erythropoietin
Monoclonal antibodies
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Others

Segmentation by application
Blood Disorders
Oncology Diseases
Chronic and Autoimmune Diseases
Growth Hormone Deficiencies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis (Sandoz)
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion Biocon
Hospira
Merck Serono (Merck)
Biogen idec
Genentech (Roche)

Please note: The report will take approximately 2 business days to prepare and deliver.